{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:27:46Z","timestamp":1789846066125,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.vaccine.2014.04.088","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T21:01:34Z","timestamp":1399669294000},"page":"3816-3822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis"],"prefix":"10.1016","volume":"32","author":[{"given":"Bhavana Sethu","family":"Lakshmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rentala","family":"Madhubala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.04.088_bib0005","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","article-title":"Leishmaniasis","volume":"354","author":"Herwaldt","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0165-6147(88)90258-1","article-title":"Recent developments in the chemotherapy of leishmaniasis","volume":"9","author":"Croft","year":"1988","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0015","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.45.8.2185-2197.2001","article-title":"Clinical and experimental advances in treatment of visceral leishmaniasis","volume":"45","author":"Murray","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drup.2004.07.002","article-title":"Leishmaniasis: drugs in the clinic, resistance and new developments","volume":"7","author":"Ouellette","year":"2004","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0025","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1566524043360203","article-title":"Leishmaniasis: current status of vaccine development","volume":"4","author":"Sukumaran","year":"2004","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0045","first-page":"173","article-title":"Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major","volume":"84","author":"Xu","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0050","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.90.24.11473","article-title":"Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63","volume":"90","author":"Connell","year":"1993","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0055","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0060","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1016\/j.vaccine.2012.07.004","article-title":"Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB\/c mice against Leishmania major infection","volume":"30","author":"Hugentobler","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0065","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0070","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-2478(99)00146-7","article-title":"The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes","volume":"70","author":"Trujillo","year":"1999","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0085","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.vaccine.2008.12.053","article-title":"KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major","volume":"27","author":"Bhaumik","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0090","first-page":"423","article-title":"Leishmaniasis vaccine candidates for development: a global overview","volume":"123","author":"Khamesipour","year":"2006","journal-title":"Indian J Med Res"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2014.04.088_bib0095","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1017\/S0031182006001831","article-title":"Leishmania vaccines: progress and problems","volume":"133","author":"Kedzierski","year":"2006","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0974-777X.62881","article-title":"Leishmaniasis vaccine where are we today?","volume":"2","author":"Kedzierski","year":"2010","journal-title":"J Global Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.1112680","article-title":"The genome of the kinetoplastid parasite, Leishmania major","volume":"309","author":"Ivens","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0110","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"Peacock","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/molbev\/msp214","article-title":"The evolution of amastin surface glycoproteins in trypanosomatid parasites","volume":"27","author":"Jackson","year":"2010","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0120","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.4049\/jimmunol.0900132","article-title":"Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani","volume":"183","author":"Sharma","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0125","doi-asserted-by":"crossref","first-page":"D98","DOI":"10.1093\/nar\/gkr1032","article-title":"GeneDB\u2014an annotation database for pathogens","volume":"40","author":"Logan-Klumpler","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0130","doi-asserted-by":"crossref","first-page":"D1118","DOI":"10.1093\/nar\/gkr1053","article-title":"TDR targets: a chemogenomics resource for neglected diseases","volume":"40","author":"Magarinos","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.iy.13.040195.001055","article-title":"The regulation of immunity to Leishmania major","volume":"13","author":"Reiner","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0140","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.4049\/jimmunol.160.8.3949","article-title":"Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis","volume":"160","author":"Sjolander","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0145","first-page":"412","article-title":"Immunobiology of leishmaniasis","volume":"47","author":"Sharma","year":"2009","journal-title":"Indian J Exp Biol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0150","first-page":"238","article-title":"Immune response to Leishmania infection","volume":"119","author":"Awasthi","year":"2004","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1756-3305-4-150","article-title":"Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation","volume":"4","author":"Carrion","year":"2011","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0160","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/IAI.62.3.1058-1063.1994","article-title":"Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis","volume":"62","author":"Miralles","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0165","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0264-410X(02)00352-3","article-title":"Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani","volume":"21","author":"Sukumaran","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/IAI.61.3.1069-1073.1993","article-title":"Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis","volume":"61","author":"Kemp","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0175","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1086\/315890","article-title":"Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis","volume":"182","author":"Murray","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0180","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.4049\/jimmunol.138.7.2290","article-title":"Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma","volume":"138","author":"Murray","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0185","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI112209","article-title":"Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis","volume":"76","author":"Carvalho","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0190","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0090-1229(90)90038-R","article-title":"Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production","volume":"57","author":"Zwingenberger","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0195","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T","article-title":"IL-10 mediates susceptibility to Leishmania donovani infection","volume":"31","author":"Murphy","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2012.00251","article-title":"Immunobiology of visceral leishmaniasis","volume":"3","author":"Kumar","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0205","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","author":"Basu","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0210","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s12010-012-9649-0","article-title":"A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp","volume":"167","author":"John","year":"2012","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0215","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/IAI.57.10.3091-3096.1989","article-title":"Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters","volume":"57","author":"Gifawesen","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0220","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.42.2.702-707.1983","article-title":"Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis","volume":"42","author":"Haldar","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0225","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.144.12.4794","article-title":"Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from l-arginine","volume":"144","author":"Liew","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0230","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.4049\/jimmunol.145.12.4290","article-title":"Leishmania major amastigotes initiate the l-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha","volume":"145","author":"Green","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0235","first-page":"556","article-title":"Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from l-arginine","volume":"71","author":"Liew","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0240","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/375408a0","article-title":"Altered immune responses in mice lacking inducible nitric oxide synthase","volume":"375","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1074-7613(00)80004-7","article-title":"Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase","volume":"10","author":"Shiloh","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0250","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1172\/JCI119473","article-title":"Perspectives series: host\/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity","volume":"99","author":"Fang","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0255","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/eji.1830240328","article-title":"Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major","volume":"24","author":"Assreuy","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.088_bib0260","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/eji.1830250329","article-title":"Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo","volume":"25","author":"Germann","year":"1995","journal-title":"Eur J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T01:01:06Z","timestamp":1689210066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14006392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":52,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0264410X14006392"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}